Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. / Høiby, Niels.

In: B M C Medicine, Vol. 9, 01.01.2011, p. 32.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Høiby, N 2011, 'Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis', B M C Medicine, vol. 9, pp. 32. https://doi.org/10.1186/1741-7015-9-32, https://doi.org/10.1186/1741-7015-9-32

APA

Høiby, N. (2011). Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. B M C Medicine, 9, 32. https://doi.org/10.1186/1741-7015-9-32, https://doi.org/10.1186/1741-7015-9-32

Vancouver

Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. B M C Medicine. 2011 Jan 1;9:32. https://doi.org/10.1186/1741-7015-9-32, https://doi.org/10.1186/1741-7015-9-32

Author

Høiby, Niels. / Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. In: B M C Medicine. 2011 ; Vol. 9. pp. 32.

Bibtex

@article{dacec95b51db4a769ee425a84735e0bc,
title = "Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis",
abstract = "Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients is caused by biofilm-growing mucoid strains. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated by chronic suppressive therapy. New results from one small trial suggest that addition of oral ciprofloxacin to inhaled tobramycin may reduce lung inflammation. Clinical trials with new formulations of old antibiotics for inhalation therapy (aztreonam lysine) against chronic P. aeruginosa infection improved patient-reported outcome, lung function, time to acute exacerbations and sputum density of P. aeruginosa. Other drugs such as quinolones are currently under investigation for inhalation therapy. A trial of the use of anti-Pseudomonas antibiotics for long-term prophylaxis showed no effect in patients who were not already infected. Use of azithromycin to treat CF patients without P. aeruginosa infection did not improve lung function. Here I review the recent advances in the treatment of P. aeruginosa lung infections with a focus on inhalation treatments targeted at prophylaxis and chronic suppressive therapy.",
author = "Niels H{\o}iby",
year = "2011",
month = jan,
day = "1",
doi = "10.1186/1741-7015-9-32",
language = "English",
volume = "9",
pages = "32",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis

AU - Høiby, Niels

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients is caused by biofilm-growing mucoid strains. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated by chronic suppressive therapy. New results from one small trial suggest that addition of oral ciprofloxacin to inhaled tobramycin may reduce lung inflammation. Clinical trials with new formulations of old antibiotics for inhalation therapy (aztreonam lysine) against chronic P. aeruginosa infection improved patient-reported outcome, lung function, time to acute exacerbations and sputum density of P. aeruginosa. Other drugs such as quinolones are currently under investigation for inhalation therapy. A trial of the use of anti-Pseudomonas antibiotics for long-term prophylaxis showed no effect in patients who were not already infected. Use of azithromycin to treat CF patients without P. aeruginosa infection did not improve lung function. Here I review the recent advances in the treatment of P. aeruginosa lung infections with a focus on inhalation treatments targeted at prophylaxis and chronic suppressive therapy.

AB - Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients is caused by biofilm-growing mucoid strains. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated by chronic suppressive therapy. New results from one small trial suggest that addition of oral ciprofloxacin to inhaled tobramycin may reduce lung inflammation. Clinical trials with new formulations of old antibiotics for inhalation therapy (aztreonam lysine) against chronic P. aeruginosa infection improved patient-reported outcome, lung function, time to acute exacerbations and sputum density of P. aeruginosa. Other drugs such as quinolones are currently under investigation for inhalation therapy. A trial of the use of anti-Pseudomonas antibiotics for long-term prophylaxis showed no effect in patients who were not already infected. Use of azithromycin to treat CF patients without P. aeruginosa infection did not improve lung function. Here I review the recent advances in the treatment of P. aeruginosa lung infections with a focus on inhalation treatments targeted at prophylaxis and chronic suppressive therapy.

U2 - 10.1186/1741-7015-9-32

DO - 10.1186/1741-7015-9-32

M3 - Journal article

VL - 9

SP - 32

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

ER -

ID: 40216878